Amphastar's Costly Pivot: Growth Masks Strain in Core Drug Portfolio

RANCHO CUCAMONGA, CA – August 06, 2026 – Amphastar Pharmaceuticals posted second-quarter results that, on the surface, paint a picture of steady execution. The biopharmaceutical company reported a 5% year-over-year revenue increase to $183.9 million and an adjusted EPS of $0.91, handily beating analyst expectations. Yet, beneath these headline figures, the financial report reveals a company navigating a treacherous transition, where the success of new products is papering over significant cracks forming in its established portfolio.

In a statement accompanying the results, President and CEO Dr. Jack Zhang noted the company “continued to navigate pricing and competitive dynamics” while achieving “overall revenue growth, expansion of gross margins, meaningful launches of new products, and continued advancement” from its pipeline. While true, the story is one of strategic substitution rather than uniform growth. Amphastar is successfully executing a difficult pivot, but the costs and risks associated with this shift are becoming increasingly apparent.

A Tale of Two Portfolios

The 5% revenue growth masks a turbulent reshuffling within Amphastar’s product lineup. The company’s workhorse products are facing intense headwinds. Sales of BAQSIMI®, the nasally administered glucagon acquired from Eli Lilly, fell 3% to $45.5 million. This decline occurred despite an increase in unit volumes, a clear signal of severe pricing pressure from rebates and discounts. While the company celebrated hitting a $175 million annual sales milestone for BAQSIMI®, this victory comes with a hefty price tag: a $100 million milestone payment due to Eli Lilly next quarter, a significant cash outlay that will test the company's balance sheet.

Meanwhile, sales of the company’s older injectable glucagon cratered, falling a staggering 42% to $11.9 million due to competition and the market’s migration toward ready-to-use products like BAQSIMI®. Sales of its epinephrine multi-dose vial also softened under competitive pressure, though this was offset by demand for its pre-filled syringe, which benefited from shortages at other suppliers.

What saved the quarter was the performance of new launches. The April 2026 debut of Ipratropium bromide, a generic inhalation product, was a standout success, contributing $8.4 million in sales. This, combined with strong contributions from other recently launched higher-margin products like iron sucrose and teriparatide, propelled the “Other products” category to a 25% increase, reaching $66.2 million. These successes were crucial in lifting the company’s overall gross margin to 50.8% from 49.6% a year ago, demonstrating the financial logic behind its portfolio diversification.

The High-Stakes Bet on Biosimilars

With its legacy generic business showing signs of strain, Amphastar is betting its future on a strategic shift toward more complex, higher-value assets: biosimilars and proprietary drugs. The company’s pipeline is the clearest indicator of this transformation. By 2026, proprietary and biosimilar products are expected to make up 85% of its pipeline, a dramatic increase from just 37% in 2021.

The crown jewel of this pipeline is a biosimilar insulin candidate, AMP-004, which is currently filed with the FDA. Targeting a market segment worth over $1.6 billion, the potential approval of this product could be a transformative event for Amphastar, positioning it as a key player in the burgeoning biosimilar insulin market, which is projected to grow to over $6 billion by the early 2030s. The company is also advancing two other biosimilar products targeting a combined market of over $3.5 billion and has in-licensed several proprietary peptides for oncology and ophthalmology.

This deliberate move up the value chain is a strategic necessity in a pharmaceutical landscape where simple generics face relentless price erosion. By leveraging its expertise in technically challenging manufacturing, Amphastar aims to build a more durable and profitable business. However, this strategy is not without risk. The development timelines are long, the regulatory hurdles are high, and the upfront investment is substantial, as reflected in the company's rising operational costs.

The Rising Cost of Transformation

The strategic pivot is evident not only in the pipeline but also in the expense lines of the income statement. Operating expenses surged during the second quarter, reflecting the significant investments required to support this transformation. Selling, distribution, and marketing costs jumped 30% to $13.3 million, driven by freight expenses and the marketing push needed to support BAQSIMI® amidst its pricing challenges.

General and administrative expenses also increased by 30% to $18.2 million, a rise attributed to higher legal fees, expenses tied to implementing a new company-wide ERP system, and increased personnel costs. Research and development expenses, the engine of the company's future, grew 10% to $22.2 million, fueled by clinical trial costs for its insulin pipeline.

These rising costs, coupled with an FDA warning letter received by its IMS subsidiary that will require an additional $2 million to $3 million in quarterly remediation expenses, are pressuring profitability. While investors cheered the top-line beat, the underlying numbers reveal a company spending heavily to secure its future, accepting near-term pain for the prospect of long-term gain from a more innovative and defensible product base.